Gout occurred in 7.4 percent of GLP-1 users, compared with 6.6 percent of those not taking the drugs about a 12 percent increase
Telehealth Support and Patient Tools Patients using Medvi have access to digital tools that allow them to track body weight, dosing schedules, and reported side effects
Of those who had used a GLP-1 agonist, just over 60% took it to treat a chronic condition like diabetes or heart disease, while 40% used it to lose weight
This apparent paradoxconcerns about testosterone reduction versus evidence of testosterone elevationreflects the complex relationship between body weight, metabolic health, and hormonal balance rather than a direct drug effect on testosterone production
Higher CAT scores for cough and phlegm are associated with more severe COPD [18]
Safety, tolerability, pharmacokinetics, and pharmacodynamics of cagrilintide with semaglutide